TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial - TALASUR

Centre François Baclesse0 个研究点目标入组 50 人开始时间: 2020年8月10日最近更新: 2021年4月5日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 50

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Patient =18 years at the day of consenting to the study
•- Provision of informed consent prior to any study specific procedures
•- Histologically confirmed diagnosis of urothelial carcinoma of the renal pelvis, ureter (upper urinary tract), bladder or urethra. Both transitional cell and mixed transitional/non-transitional cell histologies are allowed, but transitional cell carcinoma must be the predominant histology.
•- Documented Stage IV disease (T4b, N0, M0; any T, N1–N3, M0; any T, any N, M1) not candidate to a curative treatment with surgery or radiotherapy at the start of first-line platinum-based chemotherapy.
•- Patient must have completed prior to inclusion a platinum-based (cisplatin or carboplatin) polychemotherapy for at least 4 cycles of chemotherapy (until 6 cycles maximum) and have a stable disease or a partial response (PR) or a complete response (CR) from the chemotherapy according to RECIST 1.1 criteria
•- A minimum dose of 55 mg/m² of cisplatin is required in order to count for 1 cycle.
•- A minimum dose of carboplatin AUC 4.5 is required in order to count for 1 cycle
•- Eligibility based on this criterion will be established locally by the investigator by examining pre and post-chemotherapy radiological assessments (CT/MRI)
•- Neoadjuvant or adjuvant chemotherapy is allowed (with a delay of at least 12 months between the last dose of neoadjuvant or adjuvant chemotherapy and the relapse)
•- Patient must be enrolled within 8 weeks after the last dose of chemotherapy.
•- Eastern Cooperative Oncology Group (ECOG) performance status = 2;
•- Normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
•-Hemoglobin = 10.0 g/dL (patient may have been transfused before inclusion)
•- Absolute neutrophil count (ANC) =1.5 x 109/L
•-Platelet count =100 G/l
•- Total bilirubin =1.5 x institutional upper limit of normal (ULN)
•-Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) =2.5 x ULN unless liver metastases are present in which case they must be =5x ULN
•-Patient must have creatinine clearance estimated using the CKD equation of = 40 mL/min
•- Able to swallow and retain oral drug
•- Life expectancy > 12 weeks
•- Serum pregnancy test (for females of childbearing potential) negative at screening
•- Male patient able to father children and female patient of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 60 days after the last dose of treatments
•-Patient affiliated to a French Social Security System or a beneficiary of such a system
•- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
•- Optional: provision of a recent formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (or subsection thereof) from the most recent primary or metastatic tumor biopsy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

排除标准

•-Patient who has never received chemotherapy with a platinum salt (cisplatin or carboplatin) for advanced/metastatic urothelial carcinoma
•-Patient who has previously received more than one line of chemotherapy for advanced/metastatic urothelial carcinoma
•-Patient whose disease has progressed according to RECIST v1.1 criteria after the first line platinum-based chemotherapy for urothelial carcinoma. The cancer must not be in the progression phase at inclusion
•-Patient with known CNS metastases and/or carcinomatous meningitis
•-Other malignancy within the last 3 years except: adequately treated non-melanoma, skin cancer curatively treated, in situ cancer of the cervix, ductal carcinoma in situ (DCIS), localized prostate carcinoma without PSA relapse
•-Patient with myelodysplastic syndrome/acute myeloid leukemia history or with features suggestive of MDS/AML
•-Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patient with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are allowed.Current treatment with an immunosuppressant medicinal product or treatment within 7 days prior to inclusion, EXCEPT:
•oIntra-nasal, inhaled or local steroids or local steroid injections (such as intra-articular injections)
•oSystemic corticosteroids at physiological doses of = 10 mg/day of prednisone or equivalent
•oSteroids as premedication for hypersensitivity reactions (such as CT scan premedication)
•-Major surgery within 4 weeks or major radiotherapy within to starting experimental treatment. Previous palliative radiotherapy (= 10 fractions) for metastatic lesions is permitted provided that this has been completed at least one week prior to starting Talazoparib and Avelumab
•-Active viral infection (HIV, Hepatitis B/C) or known history of positive test for HIV
•-Any previous treatment with PARP inhibitor or any immunotherapy (e.g. anti-CTLA-4 or anti-PDL1/ PD1)
•-Concomitant treatment with any drug on the prohibited medication list such as live vaccines, concomitant use of strong P-gp inhibitors (cf section Prohibited concomitant treatments”) or systemic corticoids at dose > 10 mg/day prednisone or equivalent. Live vaccines administered more than 30 days before study entry are permitted
•- Clinically significant (e.g. active) cardiovascular disease cerebral vascular accident/stroke in the 3 months prior to enrollment: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (= New York Heart Association Classification Class II), serious cardiac arrhythmia requiring medication, uncontrolled high blood pressure, cerebrovascular accident, transient ischaemic attack
•-Patient considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease or any psychiatric disorder that prohibits obtaining informed consent
•-Pulmonary embolism or deep vein thrombosis within 3 months prior to inclusion (unless if stable, asymptomatic and treated with a low molecular heparin for at lea

研究者

发起方

Centre François Baclesse

相似试验

招募中

2 期

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaUrothelial Carcinoma

NCT04678362Centre Francois Baclesse50

进行中（未招募）

1 期

Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT –HER2 positive, localized esophagogastric adenocarcinomaMedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10066896Term: HER2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-006512-87-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH30

尚未招募

2 期

Maintenance bevacizumab plus erlotinib versus observation in advanced Billiary tract cancer

CTRI/2020/03/023943Tata Memorial Hospital

已完成

3 期

ALTTO(Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trialHER2/ErbB2 positive primary breast cancer

JPRN-jRCT2080220464ovartis Pharma K.K8,000

招募中

1 期

Olaparib and durvalumab before surgery as treatment for patients with a BRCA-associated triple negative subtype of breast cancer (NOBLE)Triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2022-003594-33-ITEORTC AISBL/IVZW152